Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2003 October;55(5) > Minerva Ginecologica 2003 October;55(5):373-88

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  CURRENT TOPICS IN INFERTILITY


Minerva Ginecologica 2003 October;55(5):373-88

Copyright © 2003 EDIZIONI MINERVA MEDICA

language: English

GnRH antagonist in in vitro fertilization: were we are now

Shapiro B. D., Mitchell-Leef D.


PDF  


This review focuses on the recent literature concerning the use of GnRH antagonists in ovulation induction for in vitro fertilization (IVF). The GnRH antagonists, ganirelix acetate (Orga-lutran/Antagon) and cetrorelix (Cetrotide), have come into increasingly common use since their release in the last 3 years. This class of GnRH analogue has several potential advantages over GnRH agonists. Among these advantages are: 1) shorter duration of injectable drug treatment, 2) decreased gonadotropin requirement per cycle, 3) improved patient convenience and 4) lower overall treatment cost. As clinicians gain experience with these drugs, optimal treatment paradigms will likely emerge. This review will discuss current strategies and potential applications for the GnRH antagonists.

top of page

Publication History

Cite this article as

Corresponding author e-mail